NCT06061718 is a Phase 3 clinical trial of iDose TR in Open Angle Glaucoma, sponsored by Glaukos Corporation.

Who is sponsoring NCT06061718?

NCT06061718 is sponsored by Glaukos Corporation.

What drugs are being tested in NCT06061718?

Interventions in NCT06061718: iDose TR.

What condition does NCT06061718 study?

NCT06061718 studies Open Angle Glaucoma, Ocular Hypertension.

Is NCT06061718 still recruiting?

NCT06061718 is currently active, enrolled. Last updated 3 June 2024.

Last reviewed 2024-06-03 · How we verify

NCT06061718

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Active, enrolled Phase 3 Last updated 3 June 2024

What this trial tests

Phase 3 trial testing iDose TR in Open Angle Glaucoma in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 September 2023

Primary endpoint
18 March 2024

20 December 2024

Quick facts

Lead sponsor	Glaukos Corporation
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	11 September 2023
Primary completion	18 March 2024
Estimated completion	20 December 2024
Sites	1 location across Armenia

Drugs / interventions tested

iDose TR — full drug profile →

Conditions studied

Open Angle Glaucoma — all drugs for Open Angle Glaucoma →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

Glaukos Corporation — full company profile →

Who can join

45 and older, any sex, with Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery.
Singh IP, Voskanyan LA, Barber KM, Burden JH, et al · · 2025 · cited 1× · PMID 39959854 · DOI 10.1177/25158414241310275

Verify or expand the search:

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

NCT07228221 — Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma · Phase 4 · recruiting
NCT06883123 — Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · Phase 4 · recruiting
NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT06246136 — Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery · NA · recruiting
NCT06523751 — Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy · NA · recruiting

Other Glaukos Corporation trials

Trials by the same sponsor.

NCT05119920 — Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease · Phase 2 · completed
NCT05124275 — Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia · Phase 2 · completed
NCT05127551 — Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor · NA · active not recruiting
NCT06582732 — Performance of the Travoprost Intraocular Implant · Phase 2 · completed
NCT04615403 — Study of Exchange of Travoprost Intraocular Implant · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06061718 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glaukos Corporation
Last refreshed: 3 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06061718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing